[go: up one dir, main page]

MX2010005205A - Isoformas de neurregulina solubles activas modificadas postraduccionalmente. - Google Patents

Isoformas de neurregulina solubles activas modificadas postraduccionalmente.

Info

Publication number
MX2010005205A
MX2010005205A MX2010005205A MX2010005205A MX2010005205A MX 2010005205 A MX2010005205 A MX 2010005205A MX 2010005205 A MX2010005205 A MX 2010005205A MX 2010005205 A MX2010005205 A MX 2010005205A MX 2010005205 A MX2010005205 A MX 2010005205A
Authority
MX
Mexico
Prior art keywords
translationally modified
active soluble
soluble post
neuregulin isoforms
isoforms
Prior art date
Application number
MX2010005205A
Other languages
English (en)
Other versions
MX340564B (es
Inventor
Andre Schrattenholz
Original Assignee
Proteosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteosys Ag filed Critical Proteosys Ag
Publication of MX2010005205A publication Critical patent/MX2010005205A/es
Publication of MX340564B publication Critical patent/MX340564B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con isoformas de neurregulina solubles que representan modificaciones postraduccionales de neurregulina-1 como medicamento en trastornos neurológicos relacionados con la cognición, en particular esquizofrenia y enfermedades de Alzheimer y de Parkinson.
MX2010005205A 2007-11-16 2008-11-17 Isoformas de neurregulina solubles activas modificadas post-traduccionalmente. MX340564B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98857607P 2007-11-16 2007-11-16
PCT/EP2008/009715 WO2009062750A2 (en) 2007-11-16 2008-11-17 Active soluble post-translationally modified neuregulin isoforms

Publications (2)

Publication Number Publication Date
MX2010005205A true MX2010005205A (es) 2010-10-26
MX340564B MX340564B (es) 2016-07-14

Family

ID=40545995

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005205A MX340564B (es) 2007-11-16 2008-11-17 Isoformas de neurregulina solubles activas modificadas post-traduccionalmente.

Country Status (13)

Country Link
US (9) US20100256066A1 (es)
EP (1) EP2219662B1 (es)
JP (2) JP5650537B2 (es)
CN (2) CN105561299A (es)
AU (1) AU2008323169B2 (es)
BR (2) BRPI0820538B1 (es)
CA (1) CA2705328C (es)
DK (1) DK2219662T3 (es)
ES (1) ES2414058T3 (es)
MX (1) MX340564B (es)
PT (1) PT2219662E (es)
RU (1) RU2491955C2 (es)
WO (1) WO2009062750A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1252186B1 (de) * 2000-02-11 2006-01-11 ProteoSys AG Verwendung von neuregulin-beta als indikator und/oder target
EP2219662B1 (en) 2007-11-16 2013-04-24 Mind-Nrg Sa Active soluble post-translationally modified neuregulin isoforms
CN103890007A (zh) * 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 神经调节蛋白抗体及其用途
CN102327613A (zh) * 2011-09-02 2012-01-25 浙江大学 ErbB受体激动剂在制备治疗癫痫病的药物中的应用
CN103083645A (zh) * 2011-10-27 2013-05-08 中国科学院上海生命科学研究院 神经调节素1及其受体作为制备或筛选抗癫痫药物靶点的用途
JP6342627B2 (ja) * 2013-08-02 2018-06-13 国立大学法人 東京大学 筋萎縮性側索硬化症の新規病因遺伝子
CN108732355B (zh) * 2017-04-25 2021-06-25 首都医科大学附属北京安定医院 一种测定bace1酶切nrg1活性的检测方法及其试剂盒

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US6087323A (en) * 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
US6750196B1 (en) 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
CA2306228A1 (en) 1997-10-14 1999-04-22 Cambridge Neuroscience, Inc. Therapeutic methods comprising use of a neuregulin
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
NL1014232C2 (nl) 2000-01-31 2001-08-01 Dsm Nv Zout van een melaminecondensatieproduct en een fosfor bevattend zuur.
EP1252186B1 (de) 2000-02-11 2006-01-11 ProteoSys AG Verwendung von neuregulin-beta als indikator und/oder target
US20020045577A1 (en) * 2000-02-28 2002-04-18 Decode Genetics Human schizophrenia gene
US7824923B2 (en) 2001-08-06 2010-11-02 Proteosys Ag Neuregulin-β isoforms associated with neuronal processes
CA2466478A1 (en) 2001-11-28 2003-06-05 Anges Mg, Inc. Gene therapy agents for neurodegenerative diseases
US20040191818A1 (en) * 2003-02-26 2004-09-30 O'toole Margot Mary Compositions and methods for diagnosing and treating autoimmune diseases
CA2573673A1 (en) 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
US20070190127A1 (en) * 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
WO2007113366A1 (es) * 2006-04-05 2007-10-11 Consejo Superior De Investigaciones Científicas Uso de compuestos inductores del desarrollo axonal de neuronas, composiciones terapéuticas que los contienen y sus aplicaciones
EP2219662B1 (en) 2007-11-16 2013-04-24 Mind-Nrg Sa Active soluble post-translationally modified neuregulin isoforms

Also Published As

Publication number Publication date
US20170035849A1 (en) 2017-02-09
US20210128687A1 (en) 2021-05-06
AU2008323169B2 (en) 2013-08-29
US20140243269A1 (en) 2014-08-28
JP5650537B2 (ja) 2015-01-07
MX340564B (es) 2016-07-14
EP2219662B1 (en) 2013-04-24
US12251423B2 (en) 2025-03-18
US20140243270A1 (en) 2014-08-28
JP2014193879A (ja) 2014-10-09
AU2008323169A1 (en) 2009-05-22
RU2010124429A (ru) 2011-12-27
RU2491955C2 (ru) 2013-09-10
BR122020025248B1 (pt) 2022-05-03
EP2219662A2 (en) 2010-08-25
US20100256066A1 (en) 2010-10-07
CA2705328A1 (en) 2009-05-22
WO2009062750A3 (en) 2009-09-24
US20190307848A1 (en) 2019-10-10
BRPI0820538B1 (pt) 2021-08-17
DK2219662T3 (da) 2013-06-24
JP2011503134A (ja) 2011-01-27
ES2414058T3 (es) 2013-07-18
JP5913426B2 (ja) 2016-04-27
US10813978B2 (en) 2020-10-27
US20150239948A1 (en) 2015-08-27
US10350269B2 (en) 2019-07-16
US20140323408A1 (en) 2014-10-30
CN101903036A (zh) 2010-12-01
CA2705328C (en) 2018-01-02
US20210077579A1 (en) 2021-03-18
CN105561299A (zh) 2016-05-11
PT2219662E (pt) 2013-06-28
WO2009062750A2 (en) 2009-05-22
BRPI0820538A2 (pt) 2015-06-16

Similar Documents

Publication Publication Date Title
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
MX2008009947A (es) Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos.
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
MY161415A (en) A homeopathic formulation
WO2007022470A3 (en) Methods and compositions for treating neurological disease
IN2012DN02763A (es)
AU2007257423A8 (en) Purine analogs
WO2007002516A3 (en) Improved dosage forms for movement disorder treatment
MX2020012868A (es) Metodos y composiciones para trastornos del sue?o y otros trastornos.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2010005205A (es) Isoformas de neurregulina solubles activas modificadas postraduccionalmente.
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2006048242A3 (en) Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
WO2006058868A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
MX2012013735A (es) Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos.
WO2007135426A3 (en) Treatment of neurodegeneratives diseases
MY150931A (en) Substituted oxazolidinones and their use
UA102515C2 (ru) Новая лекарственная форма
WO2007133983A3 (en) 2-aminobenzimidazoles for treating neurodegenerative diseases
MX2009009361A (es) Nueva forma de dosificacion.
MX356814B (es) Métodos y composiciones para neuroprotección.
MY148092A (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MIND-NRG SA

FG Grant or registration